TrialClinical cancer research : an official journal of the American Association for Cancer Research2015

Combination of the mTOR inhibitor ridaforolimus and the anti-IGF1R monoclonal antibody dalotuzumab: preclinical characterization and phase I clinical trial.

Serena Di Cosimo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.